Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;12:845540. doi: 10.3389/fonc.2022.845540

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Maron, Hijano, Epperly, Su, Tang, Hayden, Naik, Karol, Gottschalk, Triplett and Talleur

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Association between infection and post CD19-CAR T cell therapy immune mediated side effects. The proportion of patients experiencing at least one infection in the early post CAR T cell therapy period (day 1 to day 28), displayed by infection category and severity of CAR T cell therapy related immune mediated side effects (CRS, cytokine release syndrome; NTX, neurotoxicity; carHLH, CAR-associated hemophagocytic lymphohistiocytosis). Patients with at least 1 infection in a given category (B, bacterial; V, viral; F, fungal) are presented in the colored bars, with a patient contributing up to one infection per category. Patients not having an infection in the given category are accounted for in the gray bar. Distribution is by patients by highest grade (A) CRS and (B) neurotoxicity, or presence/absence of (C) carHLH.